2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1696

Is the Risk of Tuberculosis Increased in Behçet’s Disease Compared to Other Rheumatological Disorders After Anti-TNF-α Treatment?
Abstract Number: 2199

Is There an Association of Serum LDL, HDL and Total Cholesterol with the Development of Knee Osteoarthritis?
Abstract Number: 579

Is There an Impact of Uveitis, Psoriasis and Inflammatory Bowel Disease on Musculoskeletal Disease Activity and Function in Axial Spondyloarthritis?
Abstract Number: 437

Is There Any Relationship Between Cardiovascular Comorbidity and a Patient-Acceptable Symptom State in Psoriatic Arthritis?
Abstract Number: 910

Is There Any Role for Opioids in the Management of OA?
Abstract Number: 130

Is There Clinically Relevant Plasma Interference with ELISA Detection of APS Antibodies? Reproducibility of Serum and Plasma Testing in a Real-World Clinical Setting
Abstract Number: 2080

It Starts at Work: The Relationship Between Workplace Supports and Presenteeism Among Young Adults with Rheumatic Disease
Abstract Number: 1550

Ixekizumab Demonstrates Consistent Improvement up to Week 108 in Psoriatic Arthritis Across Individual ACR Components for Patients Naïve to Biologic DMARDs or with Previous Inadequate Response to TNF Inhibitors
Abstract Number: 1488

Ixekizumab Demonstrates Improvement Comparable to Adalimumab Across ACR Components in Biologic-Naïve Patients with Psoriatic Arthritis
Abstract Number: 1510

Ixekizumab Improves Fatigue, Pain, and Sleep up to 52 Weeks in Patients with Radiographic Axial Spondyloarthritis
Abstract Number: 1547

Ixekizumab Improves Self-reported Overall Functioning and Health as Measured by the Assessment of SpondyloArthritis International Society Health Index in Patients with Active Radiographic Axial Spondyloarthritis: 52-Week Results of Two Phase 3 Randomized Trials
Abstract Number: 2729

Ixekizumab in Non-Radiographic Axial Spondyloarthritis: Primary Results from a Phase 3 Trial
Abstract Number: 1521

Ixekizumab Is Effective in the Treatment of Radiographic Axial Spondyloarthritis Regardless of the Level of C-Reactive Protein or Magnetic Resonance Imaging Scores
Abstract Number: 434

Ixekizumab Significantly Improves Patient-reported Overall Health as Measured by SF-36 in Patients with Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 52-Week Results of Two Phase 3 Trials
Abstract Number: 1545

Ixekizumab Significantly Improves Self-reported Overall Health as Measured by Short-Form-36 in Patients with Active Non-radiographic Axial Spondyloarthritis: 16- and 52-Week Results of a Phase 3 Randomized Trial (COAST-X)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].